Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21932889 | 0.83 | — | — | |
| SCHEMBL21932867 | 0.81 | — | — | |
| SCHEMBL19611899 | 0.78 | CRBN (0.33) | — | |
| SCHEMBL19611898 | 0.78 | CRBN (0.33) | — | |
| SCHEMBL21634456 | 0.71 | CRBN (0.55) | — | |
| SCHEMBL27365248 | 0.68 | MEN1 (0.39) | — | |
| SCHEMBL21932888 | 0.67 | IKZF2 (0.33) | — | |
| SCHEMBL19612035 | 0.66 | IKZF2 (0.34) | — | |
| SCHEMBL19612034 | 0.66 | IKZF2 (0.34) | — | |
| SCHEMBL20766597 | 0.64 | CRBN (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352338-B2 | Substituted isoindolinones | BIOTHERYX, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| EP-3880669-A1 | SUBSTITUTED ISOINDOLINONES | Biotheryx, Inc. (US) | 2021-09-22 | — | — | EP | disclosed |
| CN-113423701-A | Substituted isoindolinones | 拜欧斯瑞克斯公司 | 2021-09-21 | — | — | CN | disclosed |
| US-10844039-B2 | Substituted isoindolinones | BIOTHERYX, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200325114-A1 | SUBSTITUTED ISOINDOLINONES | BIOTHERYX, INC. (US) | 2020-10-15 | — | — | US | disclosed |
| WO-2020102195-A1 | SUBSTITUTED ISOINDOLINONES | BIOTHERYX, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20200148663-A1 | SUBSTITUTED ISOINDOLINONES | BIOTHERYX, INC. | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148663-A1 | SUBSTITUTED ISOINDOLINONES | BRCA1, FANCI, GOT2 | PDE3B 2621/4885PDE3A 2348/4885 |
| US-10844039-B2 | Substituted isoindolinones | BRCA1, FANCI, GOT2 | PDE3B 2621/4885PDE3A 2348/4885 |
| US-20200325114-A1 | SUBSTITUTED ISOINDOLINONES | BRCA1, FANCI, GOT2 | PDE3B 2621/4885PDE3A 2348/4885 |
| US-11352338-B2 | Substituted isoindolinones | BRCA1, FANCI, GOT2 | PDE3B 2621/4885PDE3A 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.